The purpose of this investigation is to determine whether fetal thrombocytopenia is a risk factor for puncture site bleeding. Three groups of fetuses either with or at known risk for thrombocytopenia were identified from a prospectively maintained data base of 1,100 procedures: alloimmune thrombocytopenia (ATP, 29 cordocenteses); unexpected thrombocytopenia (53 cordoncenteses), and intravascular transfusion for fetal hemolytic anemia (194 transfusions). A fourth group (58 cordocenteses) included as a normal control consisted of all appropriately grown fetuses tested within the same gestational age range as those with ATP. In total, 276 fetal blood sampling procedures were included, of which 134 (49%) yielded a platelet count of < 120 × 103/μl and 38 (14%) a platelet count of < 50 × 103/μl. The first platelet count obtained from fetuses with ATP ranged from 1 × 103 to 159 × 103/μl. There was no correlation between the platelet count and bleeding time whether the analysis was limited to only pretreatment procedures or included all. Each fetus with unexpected thrombocytopenia was systemically ill. There was no correlation between platelet count and the duration of bleeding from the cord puncture site. Intravascular transfusion produced a significant decline in the platelet count (238 ± 66 × 103vs. 153 ± 56 × 103/μl, p < 0.001). Twenty-nine percent of the post transfusion platelet counts were below 120 × 103/μl. There was a significant negative correlation between the final platelet count and the duration of puncture site bleeding (r = ––0.178, p = 0.03) independent of either the presence of hydrops, the initial or the increase in the umbilical venous pressure during transfusion. None of the 58 control fetuses had a platelet count below 120 × 103/μl. There was no correlation between platelet number and the duration of bleeding from the puncture site in this group. Thrombocytopenia is not an independent risk factor for umbilical cord bleeding after a cordocentesis performed as described.

Keywords:
Cordocentesis, safety, Platelets, Alloimmune thrombocytopenia, Intravascular transfusion
This content is only available via PDF.
© 1995 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.